학술논문
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Document Type
Article
Author
Cavo, Michele ; Gay, Francesca; Beksac, Meral; Pantani, Lucia; Petrucci, Maria Teresa; Dimopoulos, Meletios A; Dozza, Luca; van der Holt, Bronno; Zweegman, Sonja; Oliva, Stefania; van der Velden, Vincent H J; Zamagni, Elena; Palumbo, Giuseppe A; Patriarca, Francesca; Montefusco, Vittorio; Galli, Monica; Maisnar, Vladimir; Gamberi, Barbara; Hansson, Markus; Belotti, Angelo; Pour, Ludek; Ypma, Paula; Grasso, Mariella; Croockewit, Alexsandra; Ballanti, Stelvio; Offidani, Massimo; Vincelli, Iolanda D; Zambello, Renato; Liberati, Anna Marina; Andersen, Niels Frost; Broijl, Annemiek; Troia, Rossella; Pascarella, Anna; Benevolo, Giulia; Levin, Mark-David; Bos, Gerard; Ludwig, Heinz; Aquino, Sara; Morelli, Anna Maria; Wu, Ka Lung; Boersma, Rinske; Hajek, Roman; Durian, Marc; von dem Borne, Peter A; Caravita di Toritto, Tommaso; Zander, Thilo; Driessen, Christoph; Specchia, Giorgina; Waage, Anders; Gimsing, Peter; Mellqvist, Ulf-Henrik; van Marwijk Kooy, Marinus; Minnema, Monique; Mandigers, Caroline; Cafro, Anna Maria; Palmas, Angelo; Carvalho, Susanna; Spencer, Andrew; Boccadoro, Mario; Sonneveld, Pieter
Source
In The Lancet Haematology June 2020 7(6):e456-e468
Subject
Language
ISSN
2352-3026